Cipla Q2FY27：印度收入创新高但EBITDA利润率同比降630bp、净利降35%，另含与齐鲁制药帕博利珠单抗生物类似药合作

Introduction & Market Context
Cipla presented its Q2FY27 investor results on October 27, 2026, revealing a quarter marked by geographic divergence and profitability challenges. While the Indian pharmaceutical giant achieved record revenue in its home market, year-over-year margin compression and declining profitability highlighted execution pressures across the broader portfolio. The company’s shares declined 1.85% to $1,330 following the presentation, reflecting investor concerns about the sustainability of recent improvements.
The presentation emphasized "consistent sequential growth in revenue and EBITDA," with consolidated revenue reaching INR 7,404 crore and EBITDA of INR 1,388 crore. However, year-over-year comparisons revealed a more complex picture, with EBITDA margins contracting 630 basis points from 25.0% to 18.7% and profit after tax declining 35% from INR 1,351 crore to INR 878 crore.
Quarterly Performance Highlights
As shown in the following business performance snapshot, Cipla’s Q2FY27 results demonstrated geographic strength in India offset by profitability pressures across the consolidated business.
The company’s consolidated financial performance for Q2FY27 showed revenue of INR 7,404 crore, down marginally from INR 7,589 crore in the prior-year quarter. More concerning was the EBITDA decline to INR 1,388 crore from INR 1,895 crore, representing a 26.7% year-over-year decrease. Profit after tax fell to INR 878 crore (11.9% margin) from INR 1,351 crore (17.8% margin) in Q2FY26.
The detailed financial breakdown reveals the revenue composition and year-over-year comparison across key metrics.
One India emerged as the clear standout, contributing 48% of total revenue at INR 3,516 crore and delivering 12% year-over-year growth. North America accounted for 22% of revenue at $172 million, while One Africa represented 16% at $123 million. Research and development investment totaled INR 423 crore, or 5.7% of revenue, reflecting the company’s continued focus on pipeline development.
Geographic Performance Analysis
India operations delivered what the company described as "highest-ever quarterly revenue," driven by strength across branded prescription, trade generics, and consumer health segments.
The India business demonstrated broad-based momentum. Branded prescription maintained its #2 rank in the overall chronic segment according to IQVIA data, with double-digit growth in respiratory, cardiac, urology, anti-diabetes, and dermatology therapies. The company launched several new products during the quarter, including Yurpeak, Duolin Syncrobreathe, Revesmart, and Rizontem.
Trade generics delivered strong double-digit quarter-over-quarter growth, with three brands achieving trailing twelve-month revenue exceeding INR 100 crore and five brands in the INR 50-100 crore range. The segment launched 18 new products in Q2FY27.
The company’s strategic therapeutic focus in India is illustrated in the following breakdown of key therapy areas.
Cipla maintained leadership positions across multiple therapeutic categories, with respiratory growing 11% while holding the #1 rank, urology expanding 11% at #2 rank, and anti-diabetes surging 50% despite a lower #8 ranking. The company highlighted that it remains the largest pharmaceutical company by volume in the Indian market and noted that its in-house brand Dytor has scaled to over INR 800 crore in annual revenue.
In North America, the presentation emphasized regulatory and market share achievements despite revenue remaining flat year-over-year.
The company’s generic Proventil (albuterol) ranked #1 in the U.S. market with 22% share, having supplied over 50 million inhaler units cumulatively. The FDA approval of generic Advair Diskus across all three strengths (100/50, 250/50, and 500/50 mcg) represented a significant milestone for Cipla’s U.S. respiratory franchise. Recent launches included generic Ventolin, nintedanib capsules, dapagliflozin tablets, and liraglutide injection.
The company’s ANDA and NDA portfolio demonstrates the depth of its U.S. pipeline and regulatory capabilities.
As of September 30, 2026, Cipla held 191 approved ANDAs and NDAs (including 106 from Cipla Ltd, 69 from Invagen, 9 PEPFAR approvals, and 7 partnered), with an additional 44 tentatively approved and 46 under review, bringing the total portfolio to 281 applications.
In Africa, the company reported resilient performance with South Africa private market business growing faster than the overall market.
South Africa private business revenue reached ZAR 1,294 million for Q2FY27, growing 1.3 times faster than the market according to IQVIA data. Cipla ranked #3 overall in South Africa with 8.5% market share, #2 in prescription with 8.9% share, and #3 in OTC with 7.7% share. The company’s prescription business grew 9.9% versus market growth of 6.0%, demonstrating share gains in the region.
Strategic Initiatives
Cipla announced two significant strategic alliances during the quarter aimed at strengthening its oncology and biosimilar portfolios.
The company entered an exclusive licensing agreement with CTTQ (SinoBiopharma Group) for TQB2102, an advanced bispecific HER2 antibody-drug conjugate, covering India, South Africa, and five other emerging markets. This partnership targets HER2-low breast cancer, which represents approximately 50% of breast cancer cases in India.
Additionally, Cipla formed an exclusive U.S. licensing and supply partnership with Qilu Pharmaceutical for QL2107, a pembrolizumab biosimilar (Keytruda). Under this arrangement, Qilu will lead development, regulatory registration, and supply, while Cipla will handle U.S. commercialization following regulatory approval.
ESG and Sustainability Progress
The company provided a detailed update on environmental, social, and governance initiatives for its India manufacturing operations.
Cipla reported 77% renewable electricity share against an 80% target for FY2029-30, and achieved a 44% reduction in Scope 1 and 2 GHG emissions, exceeding its 30% reduction goal. The company maintained water positivity at 2.6 times and continued its zero waste to landfill certification process. In social metrics, women’s representation in the Cipla Leadership Group reached 15.8%, progressing toward the 20% target. The company achieved Silver Certification under LEED v4 BD+C for its Kurkumbh facility and earned a Bronze Medal in EcoVadis for 2026.
Financial Position and Outlook
The consolidated profit and loss statement reveals the magnitude of profitability pressures facing the company.
Revenue from sale of products declined to INR 7,368 crore from INR 7,447 crore year-over-year, while other operating income fell sharply to INR 36 crore from INR 142 crore. Total expenses increased to INR 6,016 crore from INR 5,695 crore, driven by higher employee benefits (INR 1,475 crore versus INR 1,315 crore) and material costs (INR 2,634 crore versus INR 2,498 crore). Profit before tax declined 36.5% to INR 1,177 crore from INR 1,854 crore.
The company’s balance sheet position remained solid as of September 2026.
Equity increased to INR 35,522 crore from INR 33,025 crore year-over-year, while total debt including lease liabilities remained modest at INR 699 crore compared to INR 467 crore. Cash and cash equivalents stood at INR 10,522 crore versus INR 10,368 crore, providing financial flexibility for strategic investments. Trade receivables improved to INR 6,000 crore from INR 6,902 crore, while inventory increased to INR 6,778 crore from INR 6,160 crore.
According to the earnings call transcript, management maintained full-year EBITDA margin guidance of 18.5% to 20% and reiterated its target of reaching a $1 billion annualized North America revenue run rate by the end of FY2027. The company expects sequential margin improvement through the remainder of the fiscal year, driven by product mix optimization and the ramp-up of recently approved respiratory products in the U.S. market.
The presentation highlighted progress across multiple fronts—geographic diversification, regulatory approvals, strategic partnerships, and ESG commitments—while the underlying financials revealed execution challenges that investors will monitor closely in coming quarters.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.